Virginia 2023 Regular Session

Virginia Senate Bill SB793

Introduced
11/29/22  

Caption

COVID-19; prescriptions for hydroxychloroquine and ivermectin for treatment.

Impact

If enacted, SB793 will officially recognize and permit the use of hydroxychloroquine and ivermectin as treatment options for COVID-19 within the state. This legislation could have significant implications for the medical community, as it would not only protect prescribers from liability associated with prescribing these medications but also potentially increase their availability to patients. This move may reflect a growing trend among certain health care professionals to explore various treatment options for COVID-19, potentially leading to broader discussions around the efficacy and safety of such treatments.

Summary

SB793 seeks to amend the Code of Virginia to allow licensed health care providers to prescribe, administer, or dispense hydroxychloroquine and ivermectin for patients diagnosed with COVID-19. The bill specifically states that medical professionals will not face disciplinary action from the Board of Medicine for prescribing these medications, provided that such actions are documented in the patient's medical record. By introducing this provision, the bill aims to remove barriers for providers who choose to utilize these treatments based on their clinical judgment regarding COVID-19 patients.

Contention

The discussion surrounding SB793 has potential for notable contention, particularly regarding the medical community's divided opinions on the effectiveness of hydroxychloroquine and ivermectin in treating COVID-19. Critics may argue that endorsing these medications without sufficient evidence could lead to misuse or detract from more proven therapeutic strategies. Additionally, there may be concerns regarding the implications of providing immunity to prescribers, which some may view as a loophole that could allow for questionable medical practices. Thus, the bill's passage could spark debate over the balance between encouraging innovative treatments and ensuring patient safety.

Companion Bills

No companion bills found.

Previously Filed As

VA SB73

COVID-19; prescriptions for hydroxychloroquine and ivermectin for treatment.

VA HF1915

Pharmacists authorized to prescribe, dispense, and administer hydroxychloroquine and ivermectin for preexposure prophylaxis use, postexposure prophylaxis use, or treatment of COVID-19.

VA SF1643

Pharmacist authorization to prescribe, dispense, and administer hydroxychloroquine and ivermectin for preexposure prophylaxis use, postexposure prophylaxis use or the treatment of COVID-19

VA SB301

Relating to prescribing, administering, or dispensing ivermectin or hydroxychloroquine sulfate.

VA H3916

Ivermectin and Hydroxychloroquine

VA HB1022

Permitting pharmacists to dispense the drug Ivermectin by means of a standing order and establishing a commission to study the use of Ivermectin to treat Covid-19.

VA HF2230

All pharmacies required to make ivermectin and hydroxychloroquine available without a prescription.

VA SF2898

Ivermectin and hydroxychloroquine made available without a prescription by all pharmacies requirement

VA SB711

Prescriptions; off-label use.

VA HB102

Prescriptions; off-label use.

Similar Bills

No similar bills found.